BioIVT Webinar to Discuss Ethical and Regulatory Issues Regarding Use of Human Biospecimens in Life Sciences Research in the UK and EU
WESTBURY, NY - Mar 18, 2019 - BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it will be co-hosting a one-hour webinar entitled Gaining Clarity: Unique Considerations for the Ethical and Regulatory Use of Human Biospecimens in the European Union (EU) and United Kingdom (UK) at 8 a.m. EST on Mar. 19.
This webinar will provide an overview of ethical and regulatory issues pertaining to the collection and use of biological samples for life sciences research. Topics to be covered include current views regarding compensation versus reimbursement for biological samples, and the correct use of non-consented samples whether they are remnants from a medical procedure or the result of a consent waiver.
BioIVT developed this webinar in response to customer requests for insight and guidance on complying with all the relevant regional, country and EU regulations on the use of biological samples in life sciences research, said Cathie G. Miller, PhD, director of product marketing, personalized medicine at BioIVT and the webinar co-presenter. We are committed to sharing our expertise and helping to ensure that biological samples are appropriately sourced and consented and are delivered with detailed clinical data so they can provide maximum benefit in the research study.
WIRB-Copernicus Group (WCG) is proud to partner with BioIVT to deliver this educational webinar about best practices for ensuring regulatory compliance when using biological samples, said Troy M. Brinkman, JD, MA, CIP, director of business development at WCG and the other webinar presenter. This webinar furthers our mission to make clinical research more efficient and effective while maintaining the highest standards of human subject protection.
Mr. Brinkman is a regulatory attorney whose primary role at WCG is to help sponsors and contract research organizations partner with their institutional review boards and make more efficient and compliant decisions during the study start-up process. Dr. Miller has more than 20 years experience working with biological samples at the bench and as a director and global product manager in the oncology, immunology and virology fields.
Interested parties can register for this complimentary webinar at https://info.bioivt.com/euregulatory-wbr-reg.
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood, and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and in vitro hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit www.bioivt.com or follow the company on Twitter @BioIVT.